Deutsche Bank's research report on Retrophin, a biopharmaceutical company, highlights the company's agreement to sell a rare pediatric priority review voucher to Sanofi for $245 million. The report raises the target price for Retrophin to $52, reiterating a 'Buy' rating. The report includes financial projections, valuation metrics, and risks associated with Retrophin's business, such as sales risk, pipeline product failures, regulatory, and reimbursement risks. The report also discusses the company's financial performance, including earnings, cash flow, and balance sheet details.
documents/vol00010-efta01473355-pdf.pdf
{"title":"Deutsche Bank Markets Research on Retrophin","key_people":["Evan Seigerman","Mohit Bansal","Robyn Karnauskas"],"document_date":"27 May 2015","document_type":"financial","key_locations":["United States"],"key_organizations":["Deutsche Bank","Retrophin","Sanofi"]}